Latest & greatest articles for opioid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on opioid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on opioid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for opioid

1. Emergency Department-initiated Interventions for Patients With Opioid Use Disorder: A Systematic Review

Emergency Department-initiated Interventions for Patients With Opioid Use Disorder: A Systematic Review Emergency Department-initiated Interventions for Patients With Opioid Use Disorder: A Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public (...) at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Acad Emerg Med Actions . 2020 Jun 17. doi: 10.1111/acem.14054. Online ahead of print. Emergency Department-initiated Interventions for Patients With Opioid Use

2020 EvidenceUpdates

2. The Efficacy and Safety of Opioids in Total Joint Arthroplasty: A Direct Meta-Analysis

The Efficacy and Safety of Opioids in Total Joint Arthroplasty: A Direct Meta-Analysis The Efficacy and Safety of Opioids in Total Joint Arthroplasty: Systematic Review and Direct Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health (...) at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Arthroplasty Actions . 2020 May 27;S0883-5403(20)30572-6. doi: 10.1016/j.arth.2020.05.032. Online ahead of print. The Efficacy and Safety of Opioids in Total

2020 EvidenceUpdates

3. National Practice Guideline For the Treatment of Opioid Use Disorder

types of public sector clinics that can be authorized to prescribe the partial opioid agonist buprenorphine in outpatient settings. There is no regulation, per se, of the clinic site itself, but of the individual clinician who prescribes buprenorphine. Opiate: One of a group of alkaloids derived from the opium poppy(Papaversomniferum), with the ability to induce analgesia, euphoria, and, in higher doses, stupor, coma, and respiratory depression. The term excludes synthetic opioids. Opioid: A current (...) term for any psychoactive chemical that resembles morphine in pharmacological effects, includ- ing opiates and synthetic/semisynthetic agents that exert their effects by binding to highly selective receptors in the brain where morphine and endogenous opioids affect their actions. Opioid agonist medication: Opioid agonist medica- tions pharmacologically occupy and activate opioid receptors in the body. They thereby relieve withdrawal symptoms and reduce or extinguish cravings for opioids. Opioid

2020 Publication 4891078

4. Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder

Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review Rapid Evidence Product RRapid Evidence Product Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers (...) , Gilbert J, Hilgart J, Fiordalisi C, Hubbard K, Brandt I, Stoeger E, Paynter R, Korthuis PT, Guise J-M. Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review. (Prepared by the Scientific Resource Center under Contract No. HHSA 290-2017- 00003C). AHRQ Publication No. 20-EHC012. Rockville, MD: Agency for Healthcare Research and Quality. July 2020. Posted final reports are located on the Effective Health Care Program search page. DOI

2020 Effective Health Care Program (AHRQ)

5. HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial Full Text available with Trip Pro

HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation J Arthroplasty Actions . 2020 May 27;S0883-5403(20)30584-2. doi: 10.1016/j.arth.2020.05.044. Online ahead of print. HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial

2020 EvidenceUpdates

6. Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department

Critical Issues in the Prescribing of Opioids for Adult Patients in the Emergency Department ACEP // Opioids Popular Recommendations PEER ultrasound LLSA sepsis Log In Log In Topics Practice Education Advocacy About ACEP Topics TOPICS Quick Access Current News Practice Administration Life as a Physician Patient Care By Medical Focus Education In Education Upcoming Conferences Earn CME Now Featured Publication Advocacy Federal Advocacy State Advocacy Get Involved Groups to Join About ACEP Who We (...) Are How We Serve What We Believe Membership FEATURED BENEFIT Popular Recommendations PEER ultrasound LLSA sepsis QUICK ACCESS CURRENT NEWS TOPICS BY MEDICAL FOCUS ADMINISTRATION LIFE AS A PHYSICIAN PATIENT CARE UPCOMING CONFERENCES EARN CME NOW FEATURED PUBLICATION IN EDUCATION GROUPS TO JOIN FEDERAL ADVOCACY STATE ADVOCACY GET INVOLVED MEMBERSHIP FEATURED BENEFIT WHO WE ARE HOW WE SERVE WHAT WE BELIEVE / / Opioids Opioids (Jun 2020) Critical Issues in the Prescribing of Opioids for Adult Patients

2020 American College of Emergency Physicians

7. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis

Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Pain Med Actions . 2020 Jun 3;pnaa152. doi: 10.1093/pm/pnaa152. Online ahead of print. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis , , , , Affiliations Expand Affiliations 1 Department of Gastroenterology, The Second Affiliated

2020 EvidenceUpdates

8. New directions in the treatment of opioid withdrawal. (Abstract)

New directions in the treatment of opioid withdrawal. The treatment of opioid withdrawal is an important area of clinical concern when treating patients with chronic, non-cancer pain, patients with active opioid use disorder, and patients receiving medication for opioid use disorder. Current standards of care for medically supervised withdrawal include treatment with μ-opioid receptor agonists, (eg, methadone), partial agonists (eg, buprenorphine), and α2-adrenergic receptor agonists (eg (...) , clonidine and lofexidine). Newer agents likewise exploit these pharmacological mechanisms, including tramadol (μ-opioid receptor agonism) and tizanidine (α2 agonism). Areas for future research include managing withdrawal in the context of stabilising patients with opioid use disorder to extended-release naltrexone, transitioning patients with opioid use disorder from methadone to buprenorphine, and tapering opioids in patients with chronic, non-cancer pain.Copyright © 2020 Elsevier Ltd. All rights

2020 Lancet

9. Effect on Opioids Requirement of Early Administration of Intranasal Ketamine for Acute Traumatic Pain Full Text available with Trip Pro

Effect on Opioids Requirement of Early Administration of Intranasal Ketamine for Acute Traumatic Pain Effect on Opioids Requirement of Early Administration of Intranasal Ketamine for Acute Traumatic Pain - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center (...) Link Copy Actions Cite Share Permalink Copy Page navigation Clin J Pain Actions . 2020 Jun;36(6):458-462. doi: 10.1097/AJP.0000000000000821. Effect on Opioids Requirement of Early Administration of Intranasal Ketamine for Acute Traumatic Pain , , , , , , , , , , , Affiliations Expand Affiliations 1 Emergency Department, Fattouma Bourguiba University Hospital. 2 Research Laboratory LR12SP18, University of Monastir. 3 Emergency Department, Farhat Hached University Hospital. 4 Emergency Department

2020 EvidenceUpdates

10. Opioid-induced Euphoria Among Emergency Department Patients With Acute Severe Pain: An Analysis of Data From a Randomized Trial

. Available at: https://www.ashpintersections.org/2016/02/pharm-d-m-d-team-successfully-enacts-opioid-free-ed-shift/. Accessed November 18, 2019. Xi ZX, Stein EA. GABAergic mechanisms of opiate reinforcement. Alcohol Alcohol 2002;37:485-94. Wightman R, Perrone J, Portelli I, Nelson L. Likeability and abuse liability of commonly prescribed opioids. J Med Toxicol 2012;8:335-40. Chinn E, Friedman BW, Naeem F, et al. Randomized trial of intravenous lidocaine versus hydromorphone for acute abdominal pain (...) Opioid-induced Euphoria Among Emergency Department Patients With Acute Severe Pain: An Analysis of Data From a Randomized Trial Opioid-induced Euphoria Among Emergency Department Patients With Acute Severe Pain: An Analysis of Data From a Randomized Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health

2020 EvidenceUpdates

11. Can prescribers avoid contributing to opioid use disorder?

Can prescribers avoid contributing to opioid use disorder? Can prescribers avoid contributing to opioid use disorder? January - February 2020 Mailing Address: Therapeutics Initiative The University of British Columbia Department of Anesthesiology, Pharmacology & Therapeutics 2176 Health Sciences Mall Vancouver, BC Canada V6T 1Z3 Tel.: +1-604-822-0700 Fax: +1-604-822-0701 E-mail: info@ti.ubc.ca www.ti.ubc.ca 125 Case vignette: A 21 y/o has surgery for a condition expect- ed to improve. He fills (...) a discharge prescription for 5 days of an opioid at a standard dose. At 1-week follow-up with his family doctor for suture removal, he describes ongoing pain. Is a re - newal of opioid appropriate, potentially dangerous, or both? A ggressive promotion of opioids for chronic non-cancer pain (CNCP) began in the 1990s, cou- pled with advocacy of “pain as the 5th vital sign” and popularization of numerical scales for patients to self- rate pain. 1 Enthusiasm for this approach waned as clinical experience

2020 Therapeutics Letter

12. Tramadol: an opioid analgesic to be used with caution

Tramadol: an opioid analgesic to be used with caution Prescrire IN ENGLISH - Spotlight ''Tramadol: an opioid analgesic to be used with caution'', 1 June 2020 {1} {1} {1} | | > > > Tramadol: an opioid analgesic to be used with caution Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Tramadol: an opioid analgesic to be used with caution Classified (...) as a weak opioid, tramadol poses risks that require the same vigilance as with morphine. Tramadol is an opioid marketed for the relief of moderate to severe pain. It exposes patients to the adverse effects of opioids (intestinal, neuropsychological, and respiratory disorders, dependence and addiction, etc.), and to specific adverse effects, including hypoglycaemia and cardiac arrhythmia, with a risk of overdose in combination with other medicines or in some patients. Tramadol became the best-selling

2020 Prescrire

13. Opioid Treatments for Chronic Pain

Opioid Treatments for Chronic Pain Opioid Treatments for Chronic Pain Comparative Effectiveness Review Number 229 R Comparative Effectiveness Review Number 229 Opioid Treatments for Chronic Pain Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00009-I Prepared by: Pacific Northwest Evidence-based Practice Center Portland, OR Investigators: Roger Chou, M.D. Daniel Hartung (...) , Pharm.D. Judith Turner, Ph.D. Ian Blazina, M.P.H. Brian Chan, M.D. Ximena Levander, M.D. Marian McDonagh, Pharm.D. Shelley Selph, M.D., M.P.H. Rongwei Fu, Ph.D. Miranda Pappas, M.A. AHRQ Publication No. 20-EHC011 April 2020 ii Key Messages Purpose of Review To assess the effectiveness and harms of opioid therapy for chronic noncancer pain, alternative opioid dosing strategies, and risk mitigation strategies Key Messages • Opioids are associated with small improvements versus placebo in pain

2020 Effective Health Care Program (AHRQ)

14. Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain Full Text available with Trip Pro

Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center for Biotechnology Information (...) :3299-3317. doi: 10.2147/JPR.S231948. eCollection 2019. Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain , Affiliations Expand Affiliations 1 NEMA Research, Inc., Naples, FL, USA. 2 Neumentum, Palo Alto, CA, USA. 3 University of Arizona College of Pharmacy, Tucson, AZ, USA. 4 Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA, USA. PMID: 31997882 PMCID: DOI: Item in Clipboard Review Safety And Efficacy Of The Unique

2020 EvidenceUpdates

15. Naloxone nasal spray (Nyxoid) for opioid overdose

Naloxone nasal spray (Nyxoid) for opioid overdose Naloxone nasal spray (Nyxoid) for opioid overdose - NPS MedicineWise Log In Menu During the COVID-19 pandemic, you need to continue to take your usual medicines and stay as healthy as possible. Here is some important information for everyone to keep in mind. Featured topics 30 Mar 2020 30 Mar 2020 30 Mar 2020 Featured article Information for consumers about medicines and COVID-19 | Updated regularly as the situation changes. Keep a medicines (...) February 2020 19 February 2020 8 January 2020 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Naloxone nasal spray (Nyxoid) for opioid overdose PBS listing of naloxone nasal spray to increase naloxone use as emergency rescue treatment in the community 15 January 2020 Key points Naloxone

2020 National Prescribing Service Limited (Australia)

16. Opioids, chronic pain and the bigger picture

Opioids, chronic pain and the bigger picture OPIOID TAPERING ALGORITHM 1–9 Patient who is taking opioids No meaningful improvement in pain and/or function Cause of pain has resolved Adverse effects are intolerable Risk of harm outweighs potential benefits Signs of aberrant behaviour • Discuss the decision to taper an opioid with the patient • Ask each patient about their treatment goals and their perceived benefits and harms of opioid treatment • Listen to the patient’s beliefs and concerns (...) about, and motivations for, tapering • Discuss the benefits of tapering • Ensure the patient knows that tapering may take several months • Reassure the patient and discuss how you can monitor and support them Does the patient agree to tapering? NO • Revisit the patient’s beliefs and concerns about tapering opioids • Reinforce the rationale for tapering including potential benefits of tapering and harm of continuing long term • Assess for substance use disorder • Discuss the decision to taper

2020 National Prescribing Service Limited (Australia)

17. Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review

Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health (...) Share Permalink Copy Page navigation Pain Physician Actions . 2019 Nov;22(6):E551-E562. Prescriber Education Interventions to Optimize Opioid Prescribing in Acute Care: A Systematic Review , , , , Affiliations Expand Affiliations 1 Pharmacy Department Alfred Health, School of Public Health and Preventative Medicine Monash University, Alfred Hospital, Melbourne, Australia. 2 Pharmacy Department Alfred Health, Anaesthesia and Perioperative Medicine Department Alfred Health, Alfred Hospital, Melbourne

2020 EvidenceUpdates

18. Naldemedine (Rizmoic) - For the treatment of opioid-induced constipation (OIC)

Naldemedine (Rizmoic) - For the treatment of opioid-induced constipation (OIC) Published 13 April 2020 1 SMC2242 naldemedine 200 micrograms film-coated tablets (Rizmoic®) Shionogi BV 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission naldemedine (Rizmoic ® ) is accepted (...) for use within NHSScotland. Indication under review: For the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative. Naldemedine compared to placebo significantly improved the spontaneous bowel movement response rate in patients with opioid induced constipation and either non-cancer or cancer pain. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication For the treatment of opioid induced constipation (OIC) in adult

2020 Scottish Medicines Consortium

19. Canadian guidelines on opioid use disorder among older adults

Canadian guidelines on opioid use disorder among older adults 123 CANADIAN GERIATRICS JOURNAL, VOLUME 23, ISSUE 1, MARCH 2020 ABSTRACT Background In Canada, rates of hospital admission from opioid overdose are higher for older adults (= 65) than younger adults, and opioid use disorder (OUD) is a growing concern. In response, Health Canada commissioned the Canadian Coalition of Se- niors’ Mental Health to create guidelines for the prevention, screening, assessment, and treatment of OUD in older (...) adults. Methods A systematic review of English language literature from 2008–2018 regarding OUD in adults was conducted. Previ- ously published guidelines were evaluated using AGREE II, and key guidelines updated using ADAPTE method, by drawing on current literature. Recommendations were created and assessed using the GRADE method. Results Thirty-two recommendations were created. Prevention recom- mendations: it is key to prioritize non-pharmacological and non-opioid strategies to treat acute

2020 CPG Infobase

20. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression

Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Stay at home Only go outside for food, health reasons (...) or work (but only if you cannot work from home) If you go out, stay 2 metres (6ft) away from other people at all times Wash your hands as soon as you get home Do not meet others, even friends or family. You can spread the virus even if you don’t have symptoms. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression Benzodiazepines and opioids can both cause respiratory depression, which can be fatal if not recognised in time. Only prescribe together

2020 MHRA Drug Safety Update